Docosahexaenoic acid
|
Basic information |
| Metabolite name | Docosahexaenoic acid |
 | HMDB0002183 |
 |
C06429 |
 |
445580 |
| Synonyms | (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,1 6,19-Docosahexaenoic acid; |
| No. of studies | 28 |
|
Basic information |
| Metabolite name | Docosahexaenoic acid |
| HMDB0002183 |
|
C06429 |
|
445580 |
| Synonyms | (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,1 6,19-Docosahexaenoic acid; |
| No. of studies | 28 |
|
Relationship between Docosahexaenoic acid and depression (count: 28) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
| Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Anemarrhena saponins and Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Prefrontal cortex | Wistar rat | Down |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Prefrontal cortex | Wistar rat | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M1024 | Type1 | CUMS group vs. control group | Serum | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA1 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | CA3 region of hippocampus | ICR mouse | Down |
| Study M1024 | Type1 | CUMS group vs. control group | DG region of hippocampus | ICR mouse | Down |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | Serum | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | DG region of hippocampus | ICR mouse | Up |
| Study M1024 | Type2 | CUMS + hydroxytyrosol group vs. CUMS group | CA3 region of hippocampus | ICR mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M1032 | Type2 | CUMS + Paeonia lactiflora Pall group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1032 | Type2 | CUMS + Bupleurum chinense DC and Paeonia lactiflora Pall group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1045 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M1063 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
| Study M1087 | Type1 | CSDS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M1111 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6 mouse | Down |
| Study M1111 | Type1 | CUMS group vs. control group | Prefrontal cortex | C57BL/6 mouse | Down |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Hippocampus | C57BL/6 mouse | Up |
| Study M1111 | Type2 | CUMS + rTMS group vs. CUMS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M472 | Type3 | (2R,6R)-HNK group vs. control group | PC12 cell | Rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M582 | Type1 | CUMS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M582 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6N mouse | Down |
| Study M600 | Type1 | high-fat diet group vs. control group | Forebrain | C57BL/6J mouse | Down |
| Study M616 | Type1 | CUMS group vs. control group | Olfactory bulb | Sprague-Dawley rat | Down |
| Study M661 | Type1 | PSD group vs. stroke group | Plasma | Human | Up |
| Study M696 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M774 | Type1 | MDD group vs. control group | Serum | Human | Down |
| Study M784 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M784 | Type2 | CUMS + liquiritin group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M784 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M800 | Type3 | fluoxetine group vs. control group | Prelimbic cortex | Rhesus monkey | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running group vs. Abeta oligomer group | Serum | ICR mouse | Down |